Up-Regulation of miR-21, miR-25, miR-93, and miR-106b in Gastric Cancer

Iran Biomed J. 2018 Nov;22(6):367-73. doi: 10.29252/.22.6.367. Epub 2018 Jun 3.

Abstract

Background: Differential expression profile of microRNAs (miRNAs) could be a diagnosis signature for monitoring gastric cancer (GC) progression. In this study, we focus on the comparison of expression levels of miR-21, miR-25, miR-93, miR-106b, and miR-375 during the sequential pattern of GC development, including normal gastric, gastric dysplasia, and GC sample.

Methods: We used SYBR Green-based quantitative-PCR to quantify miRNAs expression.

Results: Our analysis revealed the increased expression levels of miR-21 (p = 0.034), miR-25 (p = 0.0003), miR-93 (p = 0.0406), and miR-106b (p = 0.023) in GC samples. In addition, GC patients with positive lymph node metastasis showed the up-regulation of miR-25, miR-93, and miR-106b (p < 0.05).

Conclusion: Our findings suggested that the expression of miR-21, miR-25, miR-93, and miR-106b altered in GC, and some of them may be further investigated as biomarkers for GC early detection and prognosis prediction.

Keywords: Biomarkers; microRNAs; Stomach cancer.

MeSH terms

  • Adult
  • Aged
  • Biomarkers, Tumor / biosynthesis*
  • Biomarkers, Tumor / genetics
  • Female
  • Gene Expression Regulation, Neoplastic
  • Humans
  • Male
  • MicroRNAs / biosynthesis*
  • MicroRNAs / genetics
  • Middle Aged
  • Retrospective Studies
  • Stomach Neoplasms / genetics
  • Stomach Neoplasms / metabolism*
  • Stomach Neoplasms / pathology
  • Up-Regulation / physiology

Substances

  • Biomarkers, Tumor
  • MIRN106 microRNA, human
  • MIRN21 microRNA, human
  • MIRN25 microRNA, human
  • MIRN93 microRNA, human
  • MicroRNAs